

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A transdermal preparation containing 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof ~~as the sole active ingredient~~, and an external preparation base.
- 2-4. (Cancelled)
5. (Currently Amended) The preparation according to ~~claim 4~~claim 1, for use as a prophylactic or therapeutic agent for preventing or treating a disorder in patients with overactive bladder, wherein the disorder is increased urinary frequency and urinary incontinence in patients with overactive bladder.
6. (Currently Amended) The preparation according to claim 1, provided in the form of ~~patch~~a patch.
7. (Original) The preparation according to claim 6, provided in the form of a single adhesive layer-type or a reservoir-type transdermal preparation.
- 8-10. (Cancelled)
11. (Currently Amended) ~~The~~A transdermal preparation for treating increased urinary frequency and urinary incontinence ~~according to claim 1~~, containing as the sole active ingredient 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof, ~~and comprising~~ an external preparation base and a structural body.
12. (Cancelled)

13. (Currently Amended) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a reservoir type preparation, comprising:

wherein a mixture of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the sole active ingredient is present in a mixture with and a single or combination one or more of the external preparation bases; and

wherein the a-structural body comprising comprises a membrane for controlling drug permeation, an adhesive layer, a support, and a peelable liner.

14-16. (Cancelled)

17. (New) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 11, which is of a single adhesive layer type preparation,

wherein 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a medically acceptable salt thereof is present in an adhesive layer containing styrene-isobutylene-styrene block copolymer and ultra-pale rosin ester as the external preparation bases; and

wherein the structural body comprises a support and a peelable liner.

18. (New) The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 13, wherein the external preparation bases comprise hydroxypropylmethylcellulose (HPMC), and ethanol/water mixture.

19. (New) The preparation according to claim 1, wherein the transdermal preparation is provided in the form of a single adhesive layer-type transdermal preparation, and the external preparation bases comprise styrene-isobutylene-styrene block copolymer and ultra-pale rosin ester.

20. (New) The preparation according to claim 1, wherein the transdermal preparation is provided in the form of a reservoir-type transdermal preparation, and the external preparation bases comprise hydroxypropylmethylcellulose (HPMC), and ethanol/water mixture.

21. (New) A method for preventing or treating increased urinary frequency or urinary incontinence in patients with overactive bladder, comprising administering a therapeutically effective amount of the preparation according to claim 1 to the patient with the overactive bladder.

22. (New) A method for preventing or treating increased urinary frequency or urinary incontinence in patients with overactive bladder, comprising administering a therapeutically effective amount of the preparation according to claim 11 to the patient with the overactive bladder.